Literature DB >> 19443884

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

Sara Simonetti1, Rosa Russo, Giuseppe Ciancia, Vincenzo Altieri, Gaetano De Rosa, Luigi Insabato.   

Abstract

This study investigates the potential clinical significance of c-erbB-2 gene and chromosome 17 alterations by fluorescence in situ hybridization (FISH) analysis and HER2/neu overexpression by immunohistochemical staining in transitional cell carcinoma (TCC) of urinary bladder correlating the results with tumor stage and grade categories and with clinical behavior. Sixty-three cases of TCC retrieved from the files of 2 institutions were analyzed for chromosome 17 aberrations and c-erbB-2 amplification by FISH analysis and evaluated immunohistochemically for HER2/neu overexpression. Five tumors were G1, 29 intermediate grade (G2), and 29 tumors high grade (G3); 32 tumors had stage Ta, 18 tumors T1, and 13 tumors T2. We found polysomy of chromosome 17 in 58.7% of TCC with average chromosome copy number >2.26; increased number of HER2/neu gene copy was observed in 66.7% of tumors. C-erbB-2 amplification occurred in 6.3% of tumors. Immunohistochemically, 60.3% of TCC overexpressed HER2/neu and 39.7% of tumors were negative. All tumors with polysomy showed simultaneously increase of HER2/neu gene copy number of which 34/37 with protein overexpression. A statistically significant correlation between polysomy of chromosome 17 and tumor stage (P = .0003) and tumor grade (P < .0001) was found; polysomy was not seen in G1 tumors; however, 8/29 G2 tumors and 29/29 G3 tumors revealed polysomy of chromosome 17; in 8/32 Ta tumors, 14/18 T1 and 13/13 of deeply invasive tumors (T2) polysomy 17 was observed. Moreover, it was found that 7 superficial tumors (1 Ta and 6 T1) showed high polysomy with average of chromosome 17 copy number > or =3.76 as observed in all invasive tumors. The data suggest that although HER2/neu amplification, found in high grade and invasive tumors, is a rare event in TCC, polysomy of chromosome 17 is an important factor correlated with tumor stage and grade categories and could be considered a molecular marker of tumor progression with interesting diagnostic implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443884     DOI: 10.1177/1066896909333415

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  16 in total

Review 1.  Emerging immunotherapies for bladder cancer.

Authors:  Joseph W Kim; Yusuke Tomita; Jane Trepel; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

2.  HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.

Authors:  Klaus Aumayr; Tobias Klatte; Barbara Neudert; Peter Birner; Shahrokh Shariat; Manuela Schmidinger; Martin Susani; Andrea Haitel
Journal:  Pathol Oncol Res       Date:  2017-07-28       Impact factor: 3.201

Review 3.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Authors:  George J Netto
Journal:  Nat Rev Urol       Date:  2011-12-13       Impact factor: 14.432

Review 4.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

5.  Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.

Authors:  Jianhong Li; Cynthia L Jackson; Dongfang Yang; Lelia Noble; Michael Wheeler; Dolores MacKenzie; Temitope Adegun; Ali Amin
Journal:  Target Oncol       Date:  2014-10-08       Impact factor: 4.493

6.  Urothelial carcinomas: a focus on human epidermal receptors signaling.

Authors:  Petros D Grivas; Mark Day; Maha Hussain
Journal:  Am J Transl Res       Date:  2011-07-25       Impact factor: 4.060

Review 7.  Targeted therapy in advanced bladder cancer: what have we learned?

Authors:  Emmet J Jordan; Gopa Iyer
Journal:  Urol Clin North Am       Date:  2015-03-12       Impact factor: 2.241

8.  HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.

Authors:  Yuka Sasaki; Takeshi Sasaki; Taketo Kawai; Teppei Morikawa; Keisuke Matsusaka; Akiko Kunita; Haruki Kume; Ichiro Aoki; Yukio Homma; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Authors:  Sumit Isharwal; Hongying Huang; Gouri Nanjangud; François Audenet; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Byron H Lee; Gopa Iyer; Kalyani Chadalavada; Jonathan E Rosenberg; Dean F Bajorin; Harry W Herr; S Machele Donat; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie
Journal:  Hum Pathol       Date:  2018-03-27       Impact factor: 3.466

10.  Evaluation of the Expression of HER2 and c-KIT Proteins as Prognostic Markers in Superficial Bladder Urothelial Carcinoma.

Authors:  Wael Abdou Hassan; Essam Shalaby; Mona Abo-Hashesh; Rehab Ibrahim Ali
Journal:  Res Rep Urol       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.